CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who have been identified as CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) via an FDA-cleared test. It is not recommended for ultra-rapid metabolizers (URMs) or indeterminate metabolizers.
- Precautions for the use of Elglustat Elglustat is a targeted therapeutic drug for Gaucher disease. During its use, relevant precautions must be strictly followed to help patients take the drug and maximize the therapeutic effect. This article will discuss in detail the precautions, specifications, properties, and dosage of Elglustat in order to provide comprehensive guidance for patients.
Jul 04, 2025, 16:25 GMT+08:00
- Side effects of Elglustat Although Elglustat is effective in improving patient symptoms, some side effects may occur during use. This article will introduce the side effects, relief measures and daily precautions of Elglustat in detail to help patients better manage the treatment process.
Jul 04, 2025, 16:22 GMT+08:00
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
- Precautions for Dacomitinib It is of great importance for both patients and doctors to understand the precautions before using dacomitinib (Vizimpro). Dacomitinib is an oral targeted therapeutic drug, commonly used in the treatment of non-small cell lung cancer (NSCLC) with EGFR gene mutations. To ensure the safety and effectiveness of the treatment, patients should understand and comply with some important precautions.
Sep 08, 2025, 17:01 GMT+08:00
- Dacomitinib: Clinical Uses, Recommended Dosage, Potential Side Effects Dacomitinib is an oral tyrosine kinase inhibitor primarily used as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR gene mutations. EGFR, a cell surface receptor, is involved in processes such as cell growth, differentiation, and survival. In some NSCLC patients, specific mutations in the EGFR gene exist (e.g., exon 19 deletion or exon 21 L858R substitution mutation). These mutations lead to abnormal activation of the EGFR signaling pathway, which in turn promotes the growth and spread of tumor cells. Currently, dacomitinib has been launched in China. This article provides a detailed description of its indications, dosage and administration, side effects, contraindications, clinical efficacy, and other aspects.
Sep 08, 2025, 16:56 GMT+08:00
Lapatinib in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapies including anthracyclines, taxanes, and trastuzumab. (Usage restriction: Before initiating treatment with lapatinib combined with capecitabine, patients must have experienced disease progression during trastuzumab treatment.)
Lapatinib in combination with letrozole is indicated for the treatment of postmenopausal women with hormone receptor-positive, metastatic breast cancer that overexpresses the HER2 receptor. The combination of lapatinib with an aromatase inhibitor (letrozole in this case) has not been compared with trastuzumab-containing chemotherapy regimens for the treatment of metastatic breast cancer.
Treatment of hyperprolactinemic disorders, whether idiopathic or due to pituitary adenomas, in adult patients.
Not indicated for inhibition or suppression of physiologic postpartum lactation.
- What versions of Cabergoline are available? And what are their respective prices? Cabergoline is a long-acting dopamine receptor agonist with high affinity for the D2 receptor. It is indicated for the treatment of hyperprolactinemia caused by primary factors or pituitary adenomas. By activating dopamine receptors, Cabergoline can inhibit the secretion of prolactin and alleviate the related symptoms in patients.
Sep 05, 2025, 16:24 GMT+08:00
- How Much Does Cabergoline Cost Annually? The annual cost of Cabergoline treatment is indeed a concern for many patients. Since the price of Cabergoline is affected by multiple factors, such as brand, purchase channel, regional differences, the patient's specific condition and medication dosage, it is impossible to provide an exact figure.
Sep 05, 2025, 16:17 GMT+08:00
VYLOY is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.
- Instructions for zotuximab (zolbetuximab) zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric cancer. Currently, zolbetuximab has not yet been launched in China. This article provides a detailed explanation of zolbetuximab, including its indications, dosage and administration, side effects, contraindications, and clinical efficacy.
Sep 01, 2025, 14:15 GMT+08:00
- Zolbetuximab: Indications, Dosage and Administration, and Precautions Zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric cancer. Currently, zolbetuximab has not yet been launched in China. This article provides a detailed explanation of zolbetuximab, including its indications, dosage and administration, side effects, contraindications, and clinical efficacy.
Sep 01, 2025, 13:57 GMT+08:00
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who have been identified as CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) via an FDA-cleared test. It is not recommended for ultra-rapid metabolizers (URMs) or indeterminate metabolizers.
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Lapatinib in combination with capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapies including anthracyclines, taxanes, and trastuzumab. (Usage restriction: Before initiating treatment with lapatinib combined with capecitabine, patients must have experienced disease progression during trastuzumab treatment.)
Lapatinib in combination with letrozole is indicated for the treatment of postmenopausal women with hormone receptor-positive, metastatic breast cancer that overexpresses the HER2 receptor. The combination of lapatinib with an aromatase inhibitor (letrozole in this case) has not been compared with trastuzumab-containing chemotherapy regimens for the treatment of metastatic breast cancer.
Treatment of hyperprolactinemic disorders, whether idiopathic or due to pituitary adenomas, in adult patients.
Not indicated for inhibition or suppression of physiologic postpartum lactation.
VYLOY is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.
HEMLIBRA is indicated for routine prophylaxis in adult and pediatric patients (newborn and older) with congenital hemophilia A (Factor VIII deficiency), regardless of inhibitor status.
- Precautions for Dacomitinib It is of great importance for both patients and doctors to understand the precautions before using dacomitinib (Vizimpro). Dacomitinib is an oral targeted therapeutic drug, commonly used in the treatment of non-small cell lung cancer (NSCLC) with EGFR gene mutations. To ensure the safety and effectiveness of the treatment, patients should understand and comply with some important precautions.
501
2025-09-08 17:01:50 - Dacomitinib: Clinical Uses, Recommended Dosage, Potential Side Effects Dacomitinib is an oral tyrosine kinase inhibitor primarily used as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR gene mutations. EGFR, a cell surface receptor, is involved in processes such as cell growth, differentiation, and survival. In some NSCLC patients, specific mutations in the EGFR gene exist (e.g., exon 19 deletion or exon 21 L858R substitution mutation). These mutations lead to abnormal activation of the EGFR signaling pathway, which in turn promotes the growth and spread of tumor cells. Currently, dacomitinib has been launched in China. This article provides a detailed description of its indications, dosage and administration, side effects, contraindications, clinical efficacy, and other aspects. 501
2025-09-08 16:56:57
- How to Buy Dacomitinib at a Lower Cost Dacomitinib, with the English name Dacomitinib, is originally developed by Pfizer Inc. of the United States. It is a highly effective drug for the treatment of metastatic non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) mutations. Its price varies depending on different versions and specifications. This article will elaborate in detail on how to purchase Dacomitinib economically. So, how to buy Dacomitinib at a lower cost? 501
2025-09-08 16:44:42
- What is the Price of Dacomitinib? Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant efficacy in the treatment of EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC). It has been launched in China and included in China's national medical insurance catalog. The original drug produced by Pfizer is available in a specification of 45mg*30 capsules, with a price of approximately 858 US dollars per box. 502
2025-09-08 16:36:50
- What Are the Purchase Channels for Dacomitinib? Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor, which has been approved in China for the first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The drug has been launched and included in the national medical insurance catalog, and patients can obtain it through a variety of formal channels. This article will detail the purchase channels of Dacomitinib. Patients can purchase this drug from hospital pharmacies, physical pharmacies, and online pharmaceutical platforms. 501
2025-09-08 16:32:55
- What Are the Purchasing Channels for Dacomitinib? Dacomitinib, also known by other names such as Vizimpro, Dacoplice, is mainly used for the treatment of metastatic non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) mutations. It has been launched in China and included in the national medical insurance catalog. Patients and their family members pay special attention to issues such as the purchasing channels of Dacomitinib. So, what are the purchasing channels for Dacomitinib? 501
2025-09-08 16:28:21
- How to Purchase Dacomitinib The original developer of Dacomitinib (Vizimpro) is Pfizer Inc. of the United States. It is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, widely used in the treatment of metastatic non-small cell lung cancer (NSCLC) with positive EGFR mutations. Then, how to purchase Dacomitinib? 501
2025-09-08 16:12:27
- What is the 2025 Latest Price of Dacomitinib? Dacomitinib, a second-generation EGFR tyrosine kinase inhibitor developed by Pfizer, is mainly used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. As a key drug in targeted therapy, its price trend, purchase methods and storage conditions have attracted much attention. Dacomitinib has been launched in China and included in the national medical insurance catalog. Then, what is the 2025 latest price of Dacomitinib? 501
2025-09-08 16:05:09
- How to Buy Dacomitinib Cost-Effectively Dacomitinib, also known by other names such as Vizimpro, Dacoplice, has multiple aliases. When purchasing Dacomitinib, patients and their family members will naturally seek the most cost-effective option. So, how to buy Dacomitinib cost-effectively? 501
2025-09-08 15:20:43
- Purchase Channels of Dacomitinib Dacomitinib, with the English name Dacomitinib, is a potent second-generation EGFR tyrosine kinase inhibitor. While patients and their family members focus on its therapeutic effects, they also need to understand Dacomitinib's purchase channels, drug interactions, and potential side effects. 501
2025-09-08 15:12:07
